Third Harmonic Bio Inc. (NASDAQ:THRD) — Market Cap & Net Worth
Market Cap & Net Worth: Third Harmonic Bio Inc. (THRD)
Third Harmonic Bio Inc. (NASDAQ:THRD) has a market capitalization of $242.79 Million ($242.79 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15870 globally and #3763 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Third Harmonic Bio Inc.'s stock price $5.38 by its total outstanding shares 45127800 (45.13 Million). Also see Third Harmonic Bio Inc. asset portfolio for a full breakdown of the balance sheet.
Third Harmonic Bio Inc. Market Cap History: 2022 to 2025
Third Harmonic Bio Inc.'s market capitalization history from 2022 to 2025. Data shows change from $194.05 Million to $242.79 Million (-32.61% CAGR). Also see Third Harmonic Bio Inc. cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Third Harmonic Bio Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #437 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1555 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.01% | #220 of 263 |
Weight: Third Harmonic Bio Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Third Harmonic Bio Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Third Harmonic Bio Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Third Harmonic Bio Inc. (THRD) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of THRD by Market Capitalization
Companies near Third Harmonic Bio Inc. in the global market cap rankings as of September 18, 2026. Review THRD goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Third Harmonic Bio Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Third Harmonic Bio Inc. Historical Marketcap From 2022 to 2025
Between 2022 and today, Third Harmonic Bio Inc.'s market cap moved from $194.05 Million to $ 242.79 Million, with a yearly change of -32.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $242.79 Million | -47.72% |
| 2024 | $464.37 Million | -6.20% |
| 2023 | $495.05 Million | +155.12% |
| 2022 | $194.05 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 12th, 2026 the market cap of Third Harmonic Bio Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $242.79 Million USD |
| MoneyControl | $242.79 Million USD |
| MarketWatch | $242.79 Million USD |
| marketcap.company | $242.79 Million USD |
| Reuters | $242.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more